Table 1.

Demographic, clinical, and treatment information of patients.

	Non-IOFB group	IOFB group	p-value
Sex			0.517b
Male, n (%)	14 (83%)	11 (91%)
Female, n (%)	3 (17%)	1 (9%)
Age, years	41.76 ± 20.05	49.08 ± 10.30	0.044a
Symptom duration, days	8.60 ± 13.26	2.47 ± 2.69	0.006a
Before treatment BCVA, LogMAR	2.27 ± 0.49	2.25 ± 0.55	0.765a
After treatment BCVA, LogMAR	1.86 ± 0.68	1.53 ± 0.83	0.116a
Maximum through-opening diameter, mm	2.53 ± 3.03	3.83 ± 1.80	0.052a
Anterior chamber flare, score	1.12 ± 1.36	1.08 ± 1.31	0.892a
Corneal penetration			0.769b
Yes	15	11
No	2	1
Sclera penetration			0.658b
Yes	13	10
No	4	2
Hypopyon			0.139b
Yes	8	9
No	9	3
Pupil exudation
Yes	8	3	0.236b
No	9	9
Presence of lens			0.131b
Yes	14	12
No	3	0
Combined lens aspiration surgery			0.175b
Yes	12	11
No	5	1
Intraoperative use of vancomycin			0.100b
Yes	11	11
No	6	1

IOFB, intraocular foreign body; BCVA, best corrected visual acuity.

^a t-test.

^b χ2 test.